Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 126
Filter
1.
Mol Cell Endocrinol ; 519: 111063, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33122102

ABSTRACT

Growth hormone (GH) promotes postnatal human growth primarily by regulating insulin-like growth factor (IGF)-I production through activation of the GH receptor (GHR)-JAK2-signal transducer and activator of transcription (STAT)-5B signaling pathway. Inactivating STAT5B mutations, both autosomal recessive (AR) and dominant-negative (DN), are causal of a spectrum of GH insensitivity (GHI) syndrome, IGF-I deficiency and postnatal growth failure. Only AR STAT5B defects, however, confer additional characteristics of immune dysfunction which can manifest as chronic, potentially fatal, pulmonary disease. Somatic activating STAT5B and JAK2 mutations are associated with a plethora of immune abnormalities but appear not to impact human linear growth. In this review, molecular defects associated with STAT5B deficiency is highlighted and insights towards understanding human growth and immunity is emphasized.


Subject(s)
Growth Disorders/metabolism , Growth Hormone/metabolism , Janus Kinase 2/metabolism , STAT5 Transcription Factor/metabolism , Body Height , Growth Disorders/immunology , Humans , STAT5 Transcription Factor/deficiency , STAT5 Transcription Factor/genetics
2.
J Immunol Res ; 2020: 9207279, 2020.
Article in English | MEDLINE | ID: mdl-32411807

ABSTRACT

Zinc is an essential element for humans, and its deficiency was documented in 1963. Nutritional zinc deficiency is now known to affect over two billion subjects in the developing world. Conditioned deficiency of zinc in many diseases has also been observed. In zinc-deficient dwarfs from the Middle East, we reported growth retardation, delayed sexual development, susceptibility to infections, poor appetite, and mental lethargy. We never found a zinc-deficient dwarf who survived beyond the age of 25 y. In an experimental model of human mild zinc deficiency, we reported decreased thymulin (a thymopoietic hormone) activity in Th1 cells, decreased mRNAs of IL-2 and IFN-gamma genes, and decreased activity of natural killer cells (NK) and T cytotoxic T cells. The effect of zinc deficiency on thymulin activity and IL-2 mRNA was seen within eight to twelve weeks of the institution of zinc-deficient diet in human volunteers, whereas lymphocyte zinc decreased in 20 weeks and plasma zinc decreased in 24 weeks after instituting zinc-deficient diet. We hypothesized that decreased thymulin activity, which is known to proliferate Th1 cells, decreased the proliferation differentiation of Th1 cells. This resulted in decreased generation of IL-2 and IFN-gamma. We observed no effect in Th2 cell function; thus, zinc deficiency resulted in an imbalance of Th1 to Th2 function resulting in decreased cell-mediated immunity. Zinc therapy may be very useful in many chronic diseases. Zinc supplementation improves cell-mediated immunity, decreases oxidative stress, and decreases generation of chronic inflammatory cytokines in humans. Development of sensitive immunological biomarkers may be more sensitive than an assay of zinc in plasma and peripheral blood cells for diagnosis of marginal zinc deficiency in human.


Subject(s)
Growth Disorders/immunology , Human Experimentation , Malnutrition/immunology , Zinc/deficiency , Biomarkers/blood , Cell Line , Cytokines/metabolism , Dietary Supplements , Female , Growth Disorders/blood , Growth Disorders/diagnosis , Growth Disorders/prevention & control , Healthy Volunteers , Humans , Immunity, Cellular , Interferon-gamma/immunology , Interferon-gamma/metabolism , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Male , Malnutrition/blood , Malnutrition/diagnosis , Malnutrition/diet therapy , Michigan , Neutrophils/immunology , Neutrophils/metabolism , Oxidative Stress/immunology , Pentosyltransferases/metabolism , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/immunology , Th2 Cells/metabolism , Zinc/administration & dosage , Zinc/blood
3.
Front Immunol ; 10: 2402, 2019.
Article in English | MEDLINE | ID: mdl-31649685

ABSTRACT

Background: Many preterm infants are born with growth restriction (GR) following maternal or fetal complications before birth. Such infants may continue to grow slowly after birth, regardless of birth weight (BW), due to morbidities related to their immature organs. Severe GR increases the susceptibility to infections, but it is not clear if this is a consequence of impaired systemic immunity or other factors, such as prolonged hospital stay or poor mucosal barrier function. Using preterm pigs as models for preterm infants, we hypothesized that moderate GR, exerting limited clinical effects, does not influence systemic immune development. Methods: Preterm pigs were delivered by cesarean section and fed bovine milk diets until 19 d. Piglets with fetal growth restriction (F-GR, the lowest 25% of BW, n = 27, excluding those with BW <350 g) and postnatal growth restriction (P-GR, the lowest 25% of postnatal growth rate, n = 24) were compared with their corresponding controls (F-CON, n = 92, and P-CON, n = 85, respectively). Organ weights were determined and blood collected for assessment of clinical status (blood chemistry and hematology). For a subgroup (n = 58), in depth analyses of neutrophil function, T cell counts, plasma cytokine levels, and leucocyte gene expression were performed. Results: For F-GR pigs, adrenal gland weight was increased and bone mineral content decreased at 19 d. Total leucocyte levels were lower at birth and interleukin-10 levels increased at d 8-10. In P-GR pigs, total leucocyte, neutrophil, monocyte, and eosinophil counts along with helper T cell fractions were elevated at 8-19 d of age, while the fraction of neutrophils with phagocytic capacity was reduced. Diarrhea and all remaining organ weights, blood chemistry, and immune variables were not affected by F-GR or P-GR. Conclusion: Moderate GR before and after preterm birth has limited effect on systemic immune development in preterm pigs, despite marginal effects on immune cell populations, adrenocortical function, and body composition. Similar responses may be observed for preterm infants with moderate fetal and postnatal growth restriction.


Subject(s)
Cytokines/immunology , Growth Disorders/immunology , Neutrophils/immunology , T-Lymphocytes/immunology , Animals , Animals, Newborn , Cytokines/blood , Disease Models, Animal , Growth Disorders/blood , Growth Disorders/pathology , Humans , Leukocyte Count , Neutrophils/metabolism , Neutrophils/pathology , Swine , T-Lymphocytes/metabolism , T-Lymphocytes/pathology
4.
J Trop Pediatr ; 65(6): 617-625, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31006009

ABSTRACT

BACKGROUND: HIV-exposed uninfected (HEU) infants show a high rate of morbidity. We aimed to investigate on biomarkers of immune activation/microbial translocation in HEU infants, evaluating the impact that infections/malnutrition can have on biomarker levels during the first year of life. METHODS: Clinical data of 72 Malawian infants were recorded monthly and correlated with levels of soluble CD14 (sCD14), lipopolysaccharide-binding protein (LBP) and intestinal fatty acid-binding protein (I-FABP), analyzed longitudinally. RESULTS: Levels of sCD14 and LBP showed a significant age-related increase. Higher levels of LBP (19.4 vs. 15.2 µg/ml) were associated with stunting, affecting 30% of the infants. The association remained statistically significant after adjusting for cytomegalovirus acquisition, malaria and respiratory infections (p = 0.031). I-FABP levels were significantly increased in infants experiencing gastrointestinal infections (1442.8 vs. 860.0 pg/ml, p = 0.018). CONCLUSION: We provide evidence that stunting is associated with an enhanced inflammatory response to microbial products in HEU children, suggesting that malnutrition status should be taken into consideration to better understand the alteration of the immune profile of HEU infants living in poor socioeconomic settings.


Subject(s)
Carrier Proteins/blood , Fatty Acid-Binding Proteins/blood , Growth Disorders/immunology , Infant Nutrition Disorders/immunology , Lipopolysaccharide Receptors/blood , Membrane Glycoproteins/blood , Acute-Phase Proteins , Anti-Retroviral Agents/therapeutic use , Bacterial Translocation , Biomarkers/blood , Female , Gastrointestinal Diseases , Growth Disorders/blood , Growth Disorders/etiology , HIV Infections/drug therapy , Humans , Infant , Infant Nutrition Disorders/blood , Infant Nutrition Disorders/complications , Malawi , Male , Pregnancy , Pregnancy Complications, Infectious/drug therapy
5.
J Clin Invest ; 128(12): 5222-5234, 2018 12 03.
Article in English | MEDLINE | ID: mdl-30179220

ABSTRACT

The mechanisms that drive T cell aging are not understood. We report that children and adult telomerase mutation carriers with short telomere length (TL) develop a T cell immunodeficiency that can manifest in the absence of bone marrow failure and causes life-threatening opportunistic infections. Mutation carriers shared T cell-aging phenotypes seen in adults 5 decades older, including depleted naive T cells, increased apoptosis, and restricted T cell repertoire. T cell receptor excision circles (TRECs) were also undetectable or low, suggesting that newborn screening may identify individuals with germline telomere maintenance defects. Telomerase-null mice with short TL showed defects throughout T cell development, including increased apoptosis of stimulated thymocytes, their intrathymic precursors, in addition to depleted hematopoietic reserves. When we examined the transcriptional programs of T cells from telomerase mutation carriers, we found they diverged from older adults with normal TL. Short telomere T cells upregulated DNA damage and intrinsic apoptosis pathways, while older adult T cells upregulated extrinsic apoptosis pathways and programmed cell death 1 (PD-1) expression. T cells from mice with short TL also showed an active DNA-damage response, in contrast with old WT mice, despite their shared propensity to apoptosis. Our data suggest there are TL-dependent and TL-independent mechanisms that differentially contribute to distinct molecular programs of T cell apoptosis with aging.


Subject(s)
Apoptosis/immunology , Growth Disorders , Hypercalcemia , Immunologic Deficiency Syndromes , Metabolic Diseases , Mutation , Nephrocalcinosis , Telomerase , Telomere Homeostasis/immunology , Adult , Aging/genetics , Aging/immunology , Aging/pathology , Animals , Apoptosis/genetics , DNA Damage/immunology , Female , Growth Disorders/complications , Growth Disorders/genetics , Growth Disorders/immunology , Growth Disorders/pathology , Humans , Hypercalcemia/complications , Hypercalcemia/genetics , Hypercalcemia/immunology , Hypercalcemia/pathology , Immunologic Deficiency Syndromes/etiology , Immunologic Deficiency Syndromes/genetics , Male , Metabolic Diseases/complications , Metabolic Diseases/genetics , Metabolic Diseases/immunology , Metabolic Diseases/pathology , Mice , Mice, Knockout , Nephrocalcinosis/complications , Nephrocalcinosis/genetics , Nephrocalcinosis/immunology , Nephrocalcinosis/pathology , Primary Immunodeficiency Diseases , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Telomerase/genetics , Telomerase/immunology
6.
BMC Pediatr ; 18(1): 236, 2018 07 19.
Article in English | MEDLINE | ID: mdl-30025542

ABSTRACT

BACKGROUND: Globally one out of four children under 5 years is affected by linear growth delay (stunting). This syndrome has severe long-term sequelae including increased risk of illness and mortality and delayed psychomotor development. Stunting is a syndrome that is linked to poor nutrition and repeated infections. To date, the treatment of stunted children is challenging as the underlying etiology and pathophysiological mechanisms remain elusive. We hypothesize that pediatric environmental enteropathy (PEE), a chronic inflammation of the small intestine, plays a major role in the pathophysiology of stunting, failure of nutritional interventions and diminished response to oral vaccines, potentially via changes in the composition of the pro- and eukaryotic intestinal communities. The main objective of AFRIBIOTA is to describe the intestinal dysbiosis observed in the context of stunting and to link it to PEE. Secondary objectives include the identification of the broader socio-economic environment and biological and environmental risk factors for stunting and PEE as well as the testing of a set of easy-to-use candidate biomarkers for PEE. We also assess host outcomes including mucosal and systemic immunity and psychomotor development. This article describes the rationale and study protocol of the AFRIBIOTA project. METHODS: AFRIBIOTA is a case-control study for stunting recruiting children in Bangui, Central African Republic and in Antananarivo, Madagascar. In each country, 460 children aged 2-5 years with no overt signs of gastrointestinal disease are recruited (260 with no growth delay, 100 moderately stunted and 100 severely stunted). We compare the intestinal microbiota composition (gastric and small intestinal aspirates; feces), the mucosal and systemic immune status and the psychomotor development of children with stunting and/or PEE compared to non-stunted controls. We also perform anthropological and epidemiological investigations of the children's broader living conditions and assess risk factors using a standardized questionnaire. DISCUSSION: To date, the pathophysiology and risk factors of stunting and PEE have been insufficiently investigated. AFRIBIOTA will add new insights into the pathophysiology underlying stunting and PEE and in doing so will enable implementation of new biomarkers and design of evidence-based treatment strategies for these two syndromes.


Subject(s)
Developing Countries , Dysbiosis/physiopathology , Enteritis/etiology , Enteritis/physiopathology , Growth Disorders/etiology , Growth Disorders/physiopathology , Social Environment , Case-Control Studies , Central African Republic , Child, Preschool , Chronic Disease , Enteritis/immunology , Enteritis/microbiology , Gastrointestinal Microbiome , Growth Disorders/immunology , Growth Disorders/microbiology , Humans , Madagascar , Nutritional Status , Poverty , Risk Factors
7.
J Endocrinol Invest ; 41(8): 919-927, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29488103

ABSTRACT

PURPOSE: To investigate whether a new liquid formulation of recombinant human growth hormone (r-hGH) induces the production of binding antibodies (BAbs) in adults with congenital or adult-onset growth hormone deficiency (GHD). METHODS: Men or women aged 19-65 years with adult growth hormone deficiency who were r-hGH-naïve or had stopped treatment ≥ 1 month before screening were treated with between 0.15 and 0.30 mg/day r-hGH liquid formulation for 39 weeks. The primary endpoint was the proportion of patients who developed BAbs at any time. Secondary endpoints were the proportion of patients with BAbs who became positive for neutralising antibodies, the effects on biomarkers of r-hGH exposure, safety, and adherence to treatment downloaded from the easypod™ connect software. RESULTS: Seventy-eight patients (61.5% men) with mean age 44.5 years (range 21-65) started and 68 (87.2%) completed the 39-week treatment period. 82.1% were treatment naïve; all were negative for BAbs to r-hGH at baseline. The median (interquartile range) duration of treatment [273 (267.0-277.0) days] was consistent with patients receiving the required doses, and mean treatment adherence measured using easypod™ connect was 89.3%. The proportion of patients who developed BAbs was 0% (95% confidence interval 0-4.68%) and biomarker profiles were consistent with exposure to r-hGH. 92.3% of patients reported ≥ 1 adverse event during treatment. Most events were mild or moderate and no new safety concerns were detected. CONCLUSIONS: The low immunogenicity profile of the liquid formulation was consistent with that for the freeze-dried formulation, and no new safety concerns were reported.


Subject(s)
Antibodies, Neutralizing/immunology , Growth Disorders/drug therapy , Human Growth Hormone/administration & dosage , Lipids/chemistry , Recombinant Proteins/administration & dosage , Adult , Aged , Antibodies, Neutralizing/chemistry , Biological Availability , Biomarkers/analysis , Female , Follow-Up Studies , Growth Disorders/immunology , Growth Disorders/metabolism , Human Growth Hormone/immunology , Humans , Male , Middle Aged , Prognosis , Recombinant Proteins/immunology , Young Adult
8.
Klin Padiatr ; 229(3): 113-117, 2017 May.
Article in English | MEDLINE | ID: mdl-28561224

ABSTRACT

Background Heterozygous point mutations in the GT splice donor consensus sequence of exon 11 of the PIK3R1 gene (coding for p85α, p55α, and p50α regulatory subunits of PI3K) lead to exon skipping and thereby to an aberrant protein that leaves PI3K hyperactivated. Several patients with this particular variant of PI3 kinase delta syndrome (APDS) suffering from sinopulmonary infections and lymphoproliferation have been described. Methods (Whole exome) sequencing, evaluation of cellular and clinical phenotypes. Results We here report a family with a new heterozygous mutation in this gene, a 9 bp deletion (c.1418_1425+1del) that, however, leads to the same skipping of exon 11. The clinical phenotypes of their members partly overlap features of patients of other reports. Conclusions We found a new mutation in PIK3R1 and show how broad the resulting clinical spectrum can be.


Subject(s)
Genetic Variation/genetics , Growth Disorders/genetics , Immunologic Deficiency Syndromes/genetics , Lymphoma/genetics , Phenotype , Phosphatidylinositol 3-Kinases/genetics , Point Mutation , B-Lymphocytes/immunology , Child , Chromosome Deletion , Class Ia Phosphatidylinositol 3-Kinase , DNA Mutational Analysis , Exons/genetics , Female , Genetic Carrier Screening , Genetic Markers/genetics , Growth Disorders/diagnosis , Growth Disorders/immunology , Humans , Immunologic Deficiency Syndromes/diagnosis , Immunologic Deficiency Syndromes/immunology , Lymphocyte Count , Lymphoma/diagnosis , Lymphoma/immunology , Pedigree , RNA Splice Sites/genetics , Exome Sequencing
9.
World J Gastroenterol ; 23(22): 3964-3977, 2017 Jun 14.
Article in English | MEDLINE | ID: mdl-28652651

ABSTRACT

Gram-negative bacteria Helicobacter pylori (H. pylori) colonize gastric mucosa in humans and increase the risk of serious diseases such as gastric and duodenal ulcers, stomach cancers and mucosa associated lymphoid tissue lymphoma. The role of H. pylori infection in the pathogenesis of several extragastric diseases has been suggested including immune thrombocytopenic purpura, iron deficiency anemia, vitamin D deficiency, cardiovascular diseases, diabetes mellitus and dermatological disorders. Also neurological diseases and even lung cancer have attracted researchers concern. The relation between H. pylori infection and a growth retardation in children has also been suggested. Many mechanisms of molecular mimicry between H. pylori and the host have been proposed as a pathogen strategy to manipulate the immune system of the host in order to remain unrecognized and avoid eradication. A lot of effort has been put into the demonstration of homologous sequences between H. pylori and host compounds. However, knowledge about how often autoantibodies or autoreactive T lymphocytes induced during H. pylori infections cause pathological disorders is insufficient. This review provides data on H. pylori antigenic mimicry and possible deleterious effects due to the induction of immune response to the components common to these bacteria and the host.


Subject(s)
Antigens, Bacterial/immunology , Autoantigens/immunology , Autoimmune Diseases/immunology , Autoimmunity , Growth Disorders/immunology , Helicobacter Infections/immunology , Helicobacter pylori/immunology , Molecular Mimicry , Animals , Antigens, Bacterial/metabolism , Autoantibodies/immunology , Autoantibodies/metabolism , Autoantigens/metabolism , Autoimmune Diseases/metabolism , Autoimmune Diseases/microbiology , Growth Disorders/metabolism , Growth Disorders/microbiology , Helicobacter Infections/metabolism , Helicobacter Infections/microbiology , Helicobacter pylori/metabolism , Helicobacter pylori/pathogenicity , Host-Pathogen Interactions , Humans , Risk Factors
10.
J Clin Invest ; 127(5): 1991-2006, 2017 May 01.
Article in English | MEDLINE | ID: mdl-28414293

ABSTRACT

Inborn errors of DNA repair or replication underlie a variety of clinical phenotypes. We studied 5 patients from 4 kindreds, all of whom displayed intrauterine growth retardation, chronic neutropenia, and NK cell deficiency. Four of the 5 patients also had postnatal growth retardation. The association of neutropenia and NK cell deficiency, which is unusual among primary immunodeficiencies and bone marrow failures, was due to a blockade in the bone marrow and was mildly symptomatic. We discovered compound heterozygous rare mutations in Go-Ichi-Ni-San (GINS) complex subunit 1 (GINS1, also known as PSF1) in the 5 patients. The GINS complex is essential for eukaryotic DNA replication, and homozygous null mutations of GINS component-encoding genes are embryonic lethal in mice. The patients' fibroblasts displayed impaired GINS complex assembly, basal replication stress, impaired checkpoint signaling, defective cell cycle control, and genomic instability, which was rescued by WT GINS1. The residual levels of GINS1 activity reached 3% to 16% in patients' cells, depending on their GINS1 genotype, and correlated with the severity of growth retardation and the in vitro cellular phenotype. The levels of GINS1 activity did not influence the immunological phenotype, which was uniform. Autosomal recessive, partial GINS1 deficiency impairs DNA replication and underlies intra-uterine (and postnatal) growth retardation, chronic neutropenia, and NK cell deficiency.


Subject(s)
DNA-Binding Proteins/deficiency , Genetic Diseases, Inborn , Growth Disorders , Immunologic Deficiency Syndromes , Killer Cells, Natural , Neutropenia , Animals , DNA-Binding Proteins/immunology , Female , Fetal Growth Retardation/genetics , Fetal Growth Retardation/immunology , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/immunology , Growth Disorders/genetics , Growth Disorders/immunology , Humans , Immunologic Deficiency Syndromes/genetics , Immunologic Deficiency Syndromes/immunology , Infant , Male , Mice , Neutropenia/genetics , Neutropenia/immunology
11.
Am J Trop Med Hyg ; 95(4): 928-937, 2016 Oct 05.
Article in English | MEDLINE | ID: mdl-27503512

ABSTRACT

Early childhood enteric infections have adverse impacts on child growth and can inhibit normal mucosal responses to oral vaccines, two critical components of environmental enteropathy. To evaluate the role of indoleamine 2,3-dioxygenase 1 (IDO1) activity and its relationship with these outcomes, we measured tryptophan and the kynurenine-tryptophan ratio (KTR) in two longitudinal birth cohorts with a high prevalence of stunting. Children in rural Peru and Tanzania (N = 494) contributed 1,251 plasma samples at 3, 7, 15, and 24 months of age and monthly anthropometrics from 0 to 36 months of age. Tryptophan concentrations were directly associated with linear growth from 1 to 8 months after biomarker assessment. A 1-SD increase in tryptophan concentration was associated with a gain in length-for-age Z-score (LAZ) of 0.17 over the next 6 months in Peru (95% confidence interval [CI] = 0.11-0.23, P < 0.001) and a gain in LAZ of 0.13 Z-scores in Tanzania (95% CI = 0.03-0.22, P = 0.009). Vaccine responsiveness data were available for Peru only. An increase in kynurenine by 1 µM was associated with a 1.63 (95% CI = 1.13-2.34) increase in the odds of failure to poliovirus type 1, but there was no association with tetanus vaccine response. A KTR of 52 was 76% sensitive and 50% specific in predicting failure of response to serotype 1 of the oral polio vaccine. KTR was associated with systemic markers of inflammation, but also interleukin-10, supporting the association between IDO1 activity and immunotolerance. These results strongly suggest that the activity of IDO1 is implicated in the pathophysiology of environmental enteropathy, and demonstrates the utility of tryptophan and kynurenine as biomarkers for this syndrome, particularly in identifying those at risk for hyporesponsivity to oral vaccines.


Subject(s)
Child Development , Citrulline/blood , Enteritis/blood , Growth Disorders/blood , Kynurenine/blood , Poliovirus Vaccine, Oral/therapeutic use , Tetanus Toxoid/therapeutic use , Tryptophan/blood , Anthropometry , Antibodies/immunology , Antibodies, Viral/immunology , Child, Preschool , Cohort Studies , Cytokines/immunology , Enteritis/immunology , Female , Growth Disorders/immunology , Humans , Infant , Inflammation , Linear Models , Male , Peru , Poliovirus Vaccine, Oral/immunology , Tanzania , Tetanus Toxoid/immunology
13.
Vaccine ; 34(20): 2312-20, 2016 Apr 29.
Article in English | MEDLINE | ID: mdl-27036512

ABSTRACT

OBJECTIVE: To determine the impact of pre-vaccination nutritional status on vaccine responses in Venezuelan Warao Amerindian children vaccinated with the 13-valent pneumococcal conjugate vaccine (PCV13) and to investigate whether saliva can be used as read-out for these vaccine responses. METHODS: A cross-sectional cohort of 504 Venezuelan Warao children aged 6 weeks - 59 months residing in nine geographically isolated Warao communities were vaccinated with a primary series of PCV13 according to Centers for Disease Control and Prevention (CDC)-recommended age-related schedules. Post-vaccination antibody concentrations in serum and saliva of 411 children were measured by multiplex immunoassay. The influence of malnutrition present upon vaccination on post-vaccination antibody levels was assessed by univariate and multivariable generalized estimating equations linear regression analysis. RESULTS: In both stunted (38%) and non-stunted (62%) children, salivary antibody concentrations correlated well with serum levels for all serotypes with coefficients varying from 0.61 for serotype 3-0.80 for serotypes 5, 6A and 23F (all p < 0.01). Surprisingly, higher serum and salivary antibody levels were observed with increasing levels of stunting in children for all serotypes. This was statistically significant for 5/13 and 11/13 serotype-specific serum and saliva IgG concentrations respectively. CONCLUSION: Stunted Amerindian children showed generally higher antibody concentrations than well-nourished children following PCV13 vaccination, indicating that chronic malnutrition influences vaccine response. Saliva samples might be useful to monitor serotype-specific antibody levels induced by PCV vaccination. This would greatly facilitate studies of vaccine efficacy in rural settings, since participant resistance generally hampers blood drawing.


Subject(s)
Antibodies, Bacterial/blood , Growth Disorders/immunology , Nutritional Status , Pneumococcal Vaccines/administration & dosage , Saliva/chemistry , Antibodies, Bacterial/chemistry , Child, Preschool , Cross-Sectional Studies , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/chemistry , Infant , Linear Models , Male , Malnutrition/immunology , Pneumococcal Infections/prevention & control , Serogroup , Streptococcus pneumoniae/classification , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/therapeutic use , Venezuela
14.
Br J Nutr ; 115(4): 567-75, 2016 Feb 28.
Article in English | MEDLINE | ID: mdl-26769562

ABSTRACT

A total of forty weaned pigs ((Landrace × Yorkshire) × Duroc) were used to evaluate the effects of Lactobacillus acidophilus on inflammatory activity after lipopolysaccharide (LPS) challenge. Experimental treatments were as follows: (T1) control diet+saline challenge; (T2) control diet with 0·1% L. acidophilus+saline challenge; (T3) control diet+LPS challenge; and (T4) control diet with 0·1% L. acidophilus+LPS challenge. On d-14, piglets were challenged with saline (T1 and T2) or LPS (T3 and T4). Blood samples were obtained at 0, 2, 4, 6 and 12 h after being challenged and analysed for immune cell cytokine production and gene expression pattern. The L. acidophilus treatment increased the average daily weight gain (ADWG) and average daily feed intake (ADFI) compared with the control diet. With the control diet, the LPS challenge (T3) increased the number of immune cells and expression of TNF-α and IL-6 compared with the saline challenge (T1). Whereas with the saline challenge L. acidophilus treatment (T2) increased the number of leucocytes and CD4 compared with the control diet (T1), with the LPS challenge L. acidophilus treatment (T4) decreased the number of leucocytes, lymphocytes, CD4+ and CD8+ and expression of TNF-α and IL-6 compared with the control diet (T3). L. acidophilus treatment decreased the expression of TRL4 and NF-κB in peripheral blood mononuclear cells (PBMC) after LPS challenge, which leads to inhibition of TNF-α, IFN-γ, IL-6, IL-8 and IL1B1 and to induction of IL-4 and IL-10. We suggested that L. acidophilus improved ADWG and ADFI and protected against LPS-induced inflammatory responses by regulating TLR4 and NF-κB expression in porcine PBMC.


Subject(s)
Animal Feed/microbiology , Down-Regulation , Immunity, Innate , Lactobacillus acidophilus/immunology , Leukocytes, Mononuclear/immunology , NF-kappa B/metabolism , Toll-Like Receptor 4/metabolism , Adaptive Immunity/drug effects , Animal Feed/adverse effects , Animals , Crosses, Genetic , Cytokines/blood , Cytokines/genetics , Cytokines/metabolism , Down-Regulation/drug effects , Energy Intake/drug effects , Growth Disorders/immunology , Growth Disorders/metabolism , Growth Disorders/prevention & control , Growth Disorders/veterinary , Immunity, Innate/drug effects , Injections, Intraperitoneal , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/toxicity , NF-kappa B/blood , NF-kappa B/genetics , Republic of Korea , Sus scrofa , Toll-Like Receptor 4/blood , Toll-Like Receptor 4/genetics , Up-Regulation/drug effects , Weaning , Weight Gain/drug effects
15.
J Clin Endocrinol Metab ; 101(3): 898-904, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26745254

ABSTRACT

CONTEXT: Type 1 diabetes mellitus (T1DM) is caused by autoimmunity against pancreatic ß-cells. Although a significant number of T1DM patients have or will develop further autoimmune disorders during their lifetime, coexisting severe immunodysregulation is rare. OBJECTIVE: Presuming autosomal-recessive inheritance in a complex immunodysregulation disorder including T1DM and short stature in two siblings, we performed whole-exome sequencing. CASE PRESENTATION: Two Libyan siblings born to consanguineous parents were presented to our diabetology department at ages 12 and 5 years, respectively. Apart from T1DM diagnosed at age 2 years, patient 1 suffered from chronic restrictive lung disease, mild enteropathy, hypogammaglobulinemia, and GH deficiency. Fluorescence-activated cell sorting analysis revealed B-cell deficiency. In addition, CD4(+)/CD25(+) and CD25(high)/FoxP3(+) cells were diminished, whereas an unusual CD25(-)/FoxP3(+) population was detectable. The younger brother, patient 2, also developed T1DM during infancy. Although his enteropathy was more severe and electrolyte derangements repeatedly led to hospitalization, he did not have significant pulmonary problems. IgG levels and B-lymphocytes were within normal ranges. RESULTS: By whole-exome sequencing we identified a homozygous truncating mutation (c.2445_2447del(C)3ins(C)2, p.P816Lfs*4) in the lipopolysaccharide-responsive beige-like anchor (LRBA) gene in both siblings. The diagnosis of LRBA deficiency was confirmed by a fluorescence-activated cell sorting-based immunoassay showing the absence of LRBA protein in phytohemagglutinin-stimulated peripheral blood mononuclear cells. CONCLUSION: We identified a novel truncating LRBA mutation in two siblings with T1DM, short stature, and severe immunodysregulation. LRBA mutations have previously been reported to cause multiorgan autoimmunity and immunodysfunction. In light of the variable phenotypes reported so far in LRBA-mutant individuals, LRBA deficiency should be considered in all patients presenting with T1DM and signs of severe immunodysregulation.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Diabetes Mellitus, Type 1/genetics , Growth Disorders/genetics , Mutation , T-Lymphocytes/immunology , Body Height , Child , Child, Preschool , Diabetes Mellitus, Type 1/immunology , Female , Growth Disorders/immunology , Humans , Male
16.
Clin Immunol ; 163: 60-5, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26748374

ABSTRACT

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a monogenic autoimmune disease characterized by early-onset life-threatening multisystemic autoimmunity. This rare hereditary disorder is caused by loss-of-function mutations in the gene encoding the forkhead box P3 (FOXP3) transcription factor, which plays a key role in the differentiation and function of CD4(+)CD25(+) natural regulatory T cells (Tregs), essential for the establishment and maintenance of natural tolerance. We identified a novel mutation in the FOXP3 gene affecting the Phe367 residue of the protein (F367V) in a family with three male siblings affected by IPEX. Two other mutations affecting the FOXP3 Phe367 residue (F367L and F367C) have been described previously. This unique situation of three mutations affecting the same residue in FOXP3 led us to study the molecular impact of these mutations on the structure of FOXP3 protein. Structure analysis showed that Phe367 is involved in a rich interaction network related to both monomer and dimer structure stabilization, and is crucial for FOXP3 regulatory activity. The relevance of this location is confirmed by the results of SIFT and PolyPhen-2 pathogenicity predictions for F367V mutation. In summary, as assessment of the pathogenicity of a novel mutation is crucial to achieve a proper molecular diagnosis, we analysed the impact of mutations affecting the Phe367 residue using a combined approach that provides a mechanistic view of their pathogenic effect.


Subject(s)
Diarrhea/genetics , Forkhead Transcription Factors/genetics , Immune System Diseases/congenital , Diabetes Mellitus, Type 1/congenital , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Diarrhea/immunology , Dimerization , Eczema/genetics , Eczema/immunology , Eosinophilia/genetics , Eosinophilia/immunology , Fatal Outcome , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/immunology , Growth Disorders/genetics , Growth Disorders/immunology , Hemorrhage/genetics , Hemorrhage/immunology , Hepatomegaly/genetics , Hepatomegaly/immunology , Humans , Hydrophobic and Hydrophilic Interactions , Immune System Diseases/genetics , Immune System Diseases/immunology , Immunoglobulin E/immunology , Infant , Klebsiella Infections/genetics , Klebsiella Infections/immunology , Leukocytosis/genetics , Leukocytosis/immunology , Lung Diseases/genetics , Lung Diseases/immunology , Male , Meningoencephalitis/genetics , Meningoencephalitis/immunology , Models, Molecular , Mutation , Phenylalanine/genetics , Sepsis/genetics , Sepsis/immunology , Splenomegaly/genetics , Splenomegaly/immunology , Thrombocytopenia/genetics , Thrombocytopenia/immunology , Thymus Gland/abnormalities
17.
Endocr Rev ; 37(1): 62-110, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26720129

ABSTRACT

Growth failure is frequently encountered in children with chronic inflammatory conditions like juvenile idiopathic arthritis, inflammatory bowel disease, and cystic fibrosis. Delayed puberty and attenuated pubertal growth spurt are often seen during adolescence. The underlying inflammatory state mediated by proinflammatory cytokines, prolonged use of glucocorticoid, and suboptimal nutrition contribute to growth failure and pubertal abnormalities. These factors can impair growth by their effects on the GH-IGF axis and also directly at the level of the growth plate via alterations in chondrogenesis and local growth factor signaling. Recent studies on the impact of cytokines and glucocorticoid on the growth plate further advanced our understanding of growth failure in chronic disease and provided a biological rationale of growth promotion. Targeting cytokines using biological therapy may lead to improvement of growth in some of these children, but approximately one-third continue to grow slowly. There is increasing evidence that the use of relatively high-dose recombinant human GH may lead to partial catch-up growth in chronic inflammatory conditions, although long-term follow-up data are currently limited. In this review, we comprehensively review the growth abnormalities in children with juvenile idiopathic arthritis, inflammatory bowel disease, and cystic fibrosis, systemic abnormalities of the GH-IGF axis, and growth plate perturbations. We also systematically reviewed all the current published studies of recombinant human GH in these conditions and discussed the role of recombinant human IGF-1.


Subject(s)
Arthritis, Juvenile/therapy , Cystic Fibrosis/therapy , Evidence-Based Medicine , Growth Disorders/prevention & control , Inflammatory Bowel Diseases/therapy , Practice Guidelines as Topic , Puberty, Delayed/prevention & control , Adolescent , Animals , Arthritis, Juvenile/immunology , Arthritis, Juvenile/pathology , Arthritis, Juvenile/physiopathology , Child , Combined Modality Therapy , Cystic Fibrosis/immunology , Cystic Fibrosis/pathology , Cystic Fibrosis/physiopathology , Drug Therapy, Combination , Growth Disorders/etiology , Growth Disorders/immunology , Growth Disorders/pathology , Growth Plate/drug effects , Growth Plate/immunology , Growth Plate/metabolism , Growth Plate/pathology , Growth Substances/genetics , Growth Substances/metabolism , Growth Substances/therapeutic use , Human Growth Hormone/genetics , Human Growth Hormone/metabolism , Human Growth Hormone/therapeutic use , Humans , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/physiopathology , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/therapeutic use , Puberty, Delayed/etiology , Puberty, Delayed/immunology , Puberty, Delayed/pathology , Recombinant Proteins/metabolism , Recombinant Proteins/therapeutic use
18.
Clin Immunol ; 163: 75-83, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26762768

ABSTRACT

DNA ligase IV (LIG4) deficiency is an extremely rare autosomal recessive primary immunodeficiency disease caused by the LIG4 mutation. To date, fewer than 30 cases of patients have been reported worldwide. No reversion mutations have been previously identified in LIG4. This study enrolled seven Chinese patients with LIG4 deficiency who presented with combined immunodeficiency, microcephaly, and growth retardation. One patient (P1) acquired non-Hodgkin lymphoma. Four patients had impaired T cell proliferation function and skewed T cell receptor diversity. Five novel mutations in LIG4 and a potential hotspot mutation (c.833G>T; p.R278L) in the Chinese population were identified. TA cloning analysis of T cells, NK cells, granulocytes, and oral mucosa cells in P6 revealed wild-type clones and clones that contained both maternally and paternally inherited mutations, indicating possible somatic reversion which need further investigation since no functional or protein assays were possible for all the patients died and no cell lines were available.


Subject(s)
DNA Ligases/genetics , Growth Disorders/genetics , Immunologic Deficiency Syndromes/genetics , Lymphoma, Non-Hodgkin/genetics , Microcephaly/genetics , T-Lymphocytes/immunology , Asian People , Cell Proliferation/genetics , Child, Preschool , China , DNA Ligase ATP , DNA Ligases/deficiency , Female , Genotype , Granulocytes/immunology , Granulocytes/metabolism , Growth Disorders/immunology , Humans , Immunologic Deficiency Syndromes/immunology , Infant , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Lymphoma, Non-Hodgkin/immunology , Male , Microcephaly/immunology , Mutation , Phenotype , Receptors, Antigen, T-Cell, alpha-beta/genetics , Syndrome , T-Lymphocytes/metabolism
19.
Neuro Endocrinol Lett ; 36(5): 458-64, 2015.
Article in English | MEDLINE | ID: mdl-26707047

ABSTRACT

OBJECTIVES: Many of peptides synthesized in gastrointestinal tract (GI) and adipose tissues, regulate growth and food intake. The GI microflora is an antigenic source. Based on the molecular mimicry hypothesis, intestinal microbe-derived antigens may trigger the production of autoantibodies cross-reacting with some neuropeptides. DESIGN: The aim of the study was to assess whether in idiopathic short stature (ISS) children with Candida albicans (C.albicans) colonisation and/or Helicobacter pylori (H.pylori) infection the autoantibodies (in positive levels) against selected neuropeptides [anti-NP Abs(+)]: ghrelin, leptin, orexin A, αMSH are more prevalent than in Controls. SETTING: The study group comprised 64 children with ISS and 36 children with normal height (Controls). In each child, IgG antibodies against H.pylori, ghrelin, leptin, orexin A and αMSH were assessed in serum, while presence of C.albicans - in stool samples. RESULTS: The higher prevalence of anti-NP Abs(+) in ISS children with C.albicans and/or H.pylori than in normal height children with the colonization in question (34.4% vs 21.1%, p<0.01) was found. The prevalence of anti-NP Abs(+) in groups of children without C.albicans and H.pylori were low, anti-NP Abs(+) were detected in 9.4% of ISS children only, while in Controls they were not found. CONCLUSIONS: In short children with C.albicans and/or H.pylori the incidence of autoantibodies against selected neuropeptides is high. It probably is connected with molecular mimicry between antigens of these microbiota and the mentioned peptides. It is tempting to speculate that presence of cross-reacting autoantibodies against regulatory neuropeptides may results in worse growth velocity. However, further studies are necessary to elucidate this issue.


Subject(s)
Autoantibodies/immunology , Candidiasis/immunology , Growth Disorders/immunology , Helicobacter Infections/immunology , Molecular Mimicry/immunology , Neuropeptides/immunology , Adolescent , Candida albicans , Carrier State/immunology , Child , Child, Preschool , Cross Reactions , Female , Ghrelin/immunology , Helicobacter pylori , Humans , Leptin/immunology , Male , Orexins/immunology , alpha-MSH/immunology
20.
J Virol ; 89(20): 10656-67, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26269184

ABSTRACT

UNLABELLED: Expression of the cytoprotective enzyme heme oxygenase-1 (HO-1) is significantly reduced in the brain prefrontal cortex of HIV-positive individuals with HIV-associated neurocognitive disorders (HAND). Furthermore, this HO-1 deficiency correlates with brain viral load, markers of macrophage activation, and type I interferon responses. In vitro, HIV replication in monocyte-derived macrophages (MDM) selectively reduces HO-1 protein and RNA expression and induces production of neurotoxic levels of glutamate; correction of this HO-1 deficiency reduces neurotoxic glutamate production without an effect on HIV replication. We now demonstrate that macrophage HO-1 deficiency, and the associated neurotoxin production, is a conserved feature of infection with macrophage-tropic HIV-1 strains that correlates closely with the extent of replication, and this feature extends to HIV-2 infection. We further demonstrate that this HO-1 deficiency does not depend specifically upon the HIV-1 accessory genes nef, vpr, or vpu but rather on HIV replication, even when markedly limited. Finally, antiretroviral therapy (ART) applied to MDM after HIV infection is established does not prevent HO-1 loss or the associated neurotoxin production. This work defines a predictable relationship between HIV replication, HO-1 loss, and neurotoxin production in MDM that likely reflects processes in place in the HIV-infected brains of individuals receiving ART. It further suggests that correcting this HO-1 deficiency in HIV-infected MDM could provide neuroprotection above that provided by current ART or proposed antiviral therapies directed at limiting Nef, Vpr, or Vpu functions. The ability of HIV-2 to reduce HO-1 expression suggests that this is a conserved phenotype among macrophage-tropic human immunodeficiency viruses that could contribute to neuropathogenesis. IMPORTANCE: The continued prevalence of HIV-associated neurocognitive disorders (HAND) underscores the need for adjunctive therapy that targets the neuropathological processes that persist in antiretroviral therapy (ART)-treated HIV-infected individuals. To this end, we previously identified one such possible process, a deficiency of the antioxidative and anti-inflammatory enzyme heme oxygenase-1 (HO-1) in the brains of individuals with HAND. In the present study, our findings suggest that the HO-1 deficiency associated with excess glutamate production and neurotoxicity in HIV-infected macrophages is a highly conserved phenotype of macrophage-tropic HIV strains and that this phenotype can persist in the macrophage compartment in the presence of ART. This suggests a plausible mechanism by which HIV infection of brain macrophages in ART-treated individuals could exacerbate oxidative stress and glutamate-induced neuronal injury, each of which is associated with neurocognitive dysfunction in infected individuals. Thus, therapies that rescue the HO-1 deficiency in HIV-infected individuals could provide additional neuroprotection to ART.


Subject(s)
Anemia, Hemolytic/virology , Glutamic Acid/toxicity , Growth Disorders/virology , HIV-1/pathogenicity , HIV-2/pathogenicity , Heme Oxygenase-1/deficiency , Iron Metabolism Disorders/virology , Macrophages/virology , Anemia, Hemolytic/genetics , Anemia, Hemolytic/immunology , Animals , Anti-HIV Agents/pharmacology , Drug Resistance, Viral/genetics , Drug Resistance, Viral/immunology , Gene Expression , Glutamic Acid/biosynthesis , Growth Disorders/genetics , Growth Disorders/immunology , HIV-1/immunology , HIV-2/immunology , Heme Oxygenase-1/genetics , Heme Oxygenase-1/immunology , Human Immunodeficiency Virus Proteins/genetics , Human Immunodeficiency Virus Proteins/immunology , Humans , Iron Metabolism Disorders/genetics , Iron Metabolism Disorders/immunology , Macrophage Activation/drug effects , Macrophages/drug effects , Macrophages/immunology , Neuroglia/drug effects , Neuroglia/immunology , Neuroglia/virology , Phenotype , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Viral Regulatory and Accessory Proteins/genetics , Viral Regulatory and Accessory Proteins/immunology , Virus Replication/drug effects , nef Gene Products, Human Immunodeficiency Virus/genetics , nef Gene Products, Human Immunodeficiency Virus/immunology , vpr Gene Products, Human Immunodeficiency Virus/genetics , vpr Gene Products, Human Immunodeficiency Virus/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...